30 September 2025 

GenIP Plc

("GenIP" or the "Company")

Commercial Strategy Update & New Products

Launching additional product lines as an AI-powered, platform-led consultancy

GenIP Plc, a technology consultancy providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to issue an update on its products and commercial strategy.

Building on the foundations of GenIP's first year since incorporation, the Company is transitioning from project-based service provider to a scalable AI-powered innovation platform, positioning for accelerated revenue growth and market penetration.

Brand consolidation, platform unity and team expansion

GenIP is consolidating its brand architecture by bringing Invention Evaluator and Talent Search (Vortechs) under a unified platform identity (GenIP.ai). This strategic move creates clear service tiers and integrated cross-selling opportunities for clients.

Invention Evaluator name and brand remain the flagship product, leveraging its strong market recognition and clear value proposition. Vortechs is being re-branded as GenIP Talent and Executive Search Services.

This consolidation strengthens brand equity while simplifying the client experience across all touchpoints.

Andrea Quiros has joined the Company to lead GenIP Talent and Executive search services. Andrea Quiros brings a wealth of experience in technical talent acquisition, having led and supported recruitment initiatives for global innovation leaders, including IBM, Palo Alto Networks, and Amazon in Central America.

Our brand consolidation, platform unity, and team expansion reflects GenIP's broader strategy to become the go-to partner for innovation triage and execution, offering a full-spectrum capability that spans GenAI-powered analysis, strategic talent acquisition, and venture-ready operational support.

Evolution to an AI-Powered, platform-led consultancy

The evolution to a platform-led client engagement model lays the foundation for:

●     Recurring SaaS-style revenues from platform-delivered services.

●     Margin expansion via automation and data re-use.

●     Defensible IP and data assets that strengthen long-term strategic position.

New Product Launches

The Company plans to launch a suite of new products and services that will expand GenIP's AI powered offering and evolve it into a more complete innovation platform. All new product lines are being powered by the highly automated Invention Evaluator platform and workflow. The consulting services are being automated through internal dashboards that streamline analysis and enable human consultants to focus on delivering strategic oversight. This ensures consistency, efficiency, and strong margins, with added value layered on top of a proven base report.

These new product offerings are designed to deepen relationships with our existing client base, and create high-margin consulting pathways as add-on services to the current entry-level Invention Evaluator report. Each add-on leverages the insights from our reports to expand into advisory, monetization, and commercialization services:

●    Invention Prioritiser - Systematically rank technology portfolios by different criteria, including technical merit, market potential, IP strength, and commercialization readiness. This helps clients decision making when allocating resources to ensure the inventions and technologies with the highest probability of impact are prioritised and de-risking decisions on weaker IP.

●    Invention Validator: Market Validation & Buyer Perception Studies - Beyond market sizing, these services design and run targeted questionnaires and stakeholder interviews to test assumptions, measure buyer interest, evaluate pricing sensitivity, and assess packaging/positioning- turning raw research into actionable market intelligence.

●     Venture & Partner Intelligence - Identify, map, and validate potential collaboration or acquisition targets, providing clients with a curated pipeline of industry partners, venture investors, and licensees aligned with their portfolio.

●     Innovation Boost - A visibility kit for technologies, including targeted materials, pitch decks, and warm introductions to industry contacts to accelerate deal flow and licensing opportunities.

●    Training & Capability Building - Practical, modular programs covering commercialization best practices, IP strategy, and partnership development. These sessions strengthen client teams and embed GenIP as a long-term strategic partner. These services, when combined, can be used to structure or scale a Technology Transfer Office (TTO).

●    Commercialisation Readiness Audits - Assess the readiness of university departments, science park tenants, or incubator cohorts to commercialize their innovations using Invention Evaluator reports as the foundation. Each audit delivers a clear, evidence-based roadmap of next steps, strengthened by a layer of human experts who interpret and prioritize the findings.

●    Portfolio Monetisation Strategy - Tailored strategies to unlock revenue pathways for universities and research organizations, built directly on the findings of Invention Evaluator reports. We identify high-potential assets and shape practical routes, licensing models, spin-out creation, and partnership structures, with added depth from a human expert layer that ensures relevance and actionability. 

●    Royalty & Licensing Benchmark - Provide deal-term benchmarks drawn from comparable transactions, enabling universities, corporates, and investors to negotiate from a position of strength.

Melissa Cruz, CEO of GenIP, commented:

"GenIP is entering its next phase of growth as an AI-powered, platform-led consultancy. By unifying our brand and expanding our product suite, we are creating a high-growth model that turns one-off projects into long-term client relationships. This is about more than new services, it's about embedding GenIP at the center of the commercialisation decision making process of research organizations and corporates.

With the Invention Evaluator report as the trusted entry point, every new product line we launch is designed to build directly on that foundation. This correlation ensures continuity for clients while multiplying the value of each engagement.

This evolution not only drives recurring, SaaS-style revenues and higher margins but also deepens our data advantage and strengthens GenIP's long-term market position. It reflects our deliberate strategy to move from being a service provider to becoming the platform of choice for universities, corporates, and investors shaping the future of innovation."

For further information regarding GenIP, please visit www.genip.ai, or contact:

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

About GenIP

GenIP is a next-generation consultancy at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

Service Offerings

GenIP operates through two synergistic service lines:

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

●     Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

●     Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

●     Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-